MAPK is a key target of CRC therapy, as blockade of EGFR is the first‐line therapy for patients with metastasized RAS/RAF‐wild‐type CRC, and combined blockade of EGFR and BRAF is first‐line therapy for patients with advanced CRC containing oncogenic BRAF mutations. This evidence concerns the gene BRAF and colorectal carcinoma.